|1.||Weller, Michael: 50 articles (12/2015 - 03/2002)|
|2.||Stupp, Roger: 45 articles (12/2015 - 03/2002)|
|3.||Wick, Wolfgang: 40 articles (10/2015 - 03/2002)|
|4.||Friedman, Henry S: 39 articles (07/2015 - 09/2002)|
|5.||Reardon, David A: 37 articles (10/2015 - 02/2003)|
|6.||Chang, Susan M: 33 articles (12/2015 - 01/2004)|
|7.||Prados, Michael D: 33 articles (08/2015 - 10/2002)|
|8.||Brandes, Alba A: 33 articles (09/2014 - 01/2002)|
|9.||Wen, Patrick Y: 30 articles (09/2015 - 11/2006)|
|10.||van den Bent, Martin J: 29 articles (12/2015 - 12/2003)|
|1.||Glioblastoma (Glioblastoma Multiforme)
09/01/2012 - "Treatment of patients with glioblastoma improved dramatically when concomitant and adjuvant temozolomide was added to external radiation therapy. "
07/15/1994 - "Temozolomide was also highly effective against intracerebral implants of the U251 and SF-295 glioblastomas. "
01/01/2014 - "Thus, microarray gene expression analysis can be effective in establishing genes affected in response to FAK inhibitor alone and in response to combination of Y15 with temozolomide that is important for glioblastoma therapy. "
06/01/2006 - "Concomitant and adjuvant treatment with Temozolomide, an oral alkylating agent, has significantly improved the survival of patients with newly diagnosed glioblastoma multiforme (study EORTC 26981/22981, NCIC CE3). "
08/01/2014 - "Considering the relative good toxicity profile and the efficacy of treatment, our experience supports the use of radiochemotherapy with temozolomide in older patients with glioblastoma."
01/01/2009 - "The efficacy of temozolomide was tested in vitro studies and has demonstrated schedule-dependent antitumor activity against highly resistant malignancies, including high-grade glioma (HGG). "
06/01/2013 - "Temozolomide is an oral alkylating agent with proven efficacy in recurrent high-grade glioma. "
07/01/2009 - "On the other hand, temozolomide (TMZ), an oral bioavailable alkylating agent with excellent tolerability, has demonstrated efficacy and has become a key therapeutic agent in patients with malignant gliomas; however, its survival benefit remains unsatisfactory. "
07/21/2003 - "Temozolomide (TMZ) is an oral alkylating agent with a good safety profile and proven efficacy in the treatment of malignant glioma. "
10/01/2000 - "Temozolomide is a novel methylating agent with proven efficacy against malignant gliomas (MGs) after systemic administration but with dose-limiting myelotoxicity. "
01/01/2013 - "For astrocytic tumors, MGMT is associated with a better prognosis and an improved response to temozolomide, and for all glial tumors, mutations in the IDH1 gene are possibly the most potent of good prognostic markers. "
11/01/2008 - "The resistance of tumors characterized by unmethylated MGMT promoter may be overcome by near continuous temozolomide administration, which is probably most effective with a 5/7-day schedule. "
04/01/2009 - "The marked improvement in clinical state of the first 2 patients accompanied by radiological evidence of tumor shrinkage in all patients demonstrates the potential use of temozolomide in treating aggressive pituitary macroadenomas. "
11/01/2006 - "The present standard of care has been shaped by the recently reported phase III study by the European Organisation for Research and Treatment of Cancer and the National Cancer Institute of Canada, which found that the addition of temozolomide (TMZ) to radiation therapy significantly improved outcome compared with radiation alone. "
09/01/2009 - "A significant reduction of tumor load was observed (P < 0.0001) in the 30% temozolomide group (approximately 95%) as compared to blank control. "
|4.||Melanoma (Melanoma, Malignant)
11/28/2006 - "Clinical trials have shown temozolomide to be an effective agent for treatment of malignant melanoma. "
01/15/2002 - "Temozolomide is a novel oral alkylating agent that is effective against melanoma. "
01/01/2015 - "Enhanced antitumor efficacy of a novel oncolytic adenovirus combined with temozolomide in the treatment of melanoma in vivo."
03/27/2004 - "Temozolomide (TMZ) displays efficacy for the treatment of metastatic melanoma. "
10/01/2015 - "Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma."
|5.||Neoplasm Metastasis (Metastasis)
02/10/2014 - "To better understand the efficacy of temozolomide in the treatment of brain metastases, we carried out a review of 21 published clinical trials to determine whether temozolomide would benefit patients with brain metastases from solid tumours. "
01/15/2002 - "Moreover, temozolomide readily crosses the blood-brain barrier and may consequently be effective in patients with brain metastases. "
07/01/2001 - "This study was designed to determine the safety and efficacy of temozolomide in the treatment of recurrent or progressive brain metastases. "
02/10/2014 - "Temozolomide for treatment of brain metastases: A review of 21 clinical trials."
11/01/2012 - "This is a phase I trial of previously irradiated patients with one to four progressive brain metastases and Karnofsky performance scale score ≥60 % enrolled in three sequential cohorts: temozolomide 100, 150 or 200 mg/(m(2) day) administered for 5 days. "
|5.||DNA (Deoxyribonucleic Acid)
|1.||Drug Therapy (Chemotherapy)
|3.||Heterologous Transplantation (Xenotransplantation)
|4.||Intensity-Modulated Radiotherapy (Radiotherapy, Intensity Modulated)